Skip to Content

Discover why overly safe playgrounds might contribute to childhood obesity and how functionality acts as the third factor explaining this surprising correlation. Question What is a plausible conclusion in this situation? It was observed that wherever playgrounds were more safe, kids gained more weight. A. Safety makes kids overweight B. The higher the weight of …

Read More about Data Science with Real World Data in Pharma: Can Safer Playgrounds Lead to Childhood Weight Gain?

Discover the top HTA agencies embracing real-world evidence (Canada, Australia, England) for regulatory decisions and improved healthcare outcomes. Question Select the most open health technology assessment agencies to using Real world evidence A. Canada B. Germany C. Australia D. England E. France Answer A. Canada C. Australia D. England Explanation The health technology assessment (HTA) …

Read More about Data Science with Real World Data in Pharma: Which Health Technology Assessment Agencies Are Leading in Real-World Evidence Adoption?

Discover which therapy (Yescarta, Evrysdi, Luxturna, Kymriah, Zolgensma, Polivy, Tecartus, or Rozlytrek) leverages real-world evidence most effectively for HTA approval across countries. Question Select the therapy with the best impact of real world evidence in most for the countries’ HTA recommendations A. Yescarta B. Evrysdi C. Luxturna D. Kymriah E. Zolgensma F. Polivy G. Tecartus …

Read More about Data Science with Real World Data in Pharma: Which Therapy Demonstrates the Strongest Real-World Evidence Impact on HTA Recommendations Globally?

Discover why none of the listed therapies (Tecartus, Rozlytrek, Zolgensma, etc.) achieved full agreement between regulatory approval and HTA reimbursement decisions. Question Select the therapies where Regulators and Health technology assessment bodies agreed on the decision A. Tecartus B. Rozlytrek C. Polivy D. Zolgensma E. Yescarta F. Kymriah G. Luxturna H. Evrysdi I. None Answer …

Read More about Data Science with Real World Data in Pharma: Which Therapies Achieved Alignment Between Regulators and Health Technology Assessment Bodies?

Discover how real-world evidence (RWE) addresses long-term treatment effects, fills evidence gaps, and enhances decision-making in health technology assessments (HTA). Question Select the focus of real world evidence in recent health technology assessment dossiers A. Effectiveness of the treatment B. Effectiveness of the comparator C. Long term treatment effect Answer C. Long term treatment effect …

Read More about Data Science with Real World Data in Pharma: What Is the Primary Focus of Real-World Evidence in Recent Health Technology Assessments?

Discover which recent FDA drug approvals, including Prograf for lung transplants, utilized real-world evidence (RWE) to demonstrate efficacy and safety. Question Select recent FDA approvals based on real world evidence A. Prograf B. Zolgensma C. Crenezumab Answer A. Prograf Explanation Explanation of FDA Approvals Based on Real-World Evidence (RWE) Prograf (tacrolimus) Approval Context: In July …

Read More about Data Science with Real World Data in Pharma: Which Recent FDA Approvals Leveraged Real-World Evidence in Drug Development?

Discover which prostate cancer patient groups (metastatic, progressing to metastatic) show the greatest benefit from novel therapies like NXP800 and next-gen hormone inhibitors, based on 2025 clinical trial data. Question Based on the study’s findings, which patients may benefit the most from the development of new treatments for prostate cancer? (Select all that apply) A. …

Read More about Data Science with Real World Data in Pharma: Which Prostate Cancer Patients Benefit Most from New Treatments?

Discover the meaning of a hazard ratio (HR) < 1 in treatment comparisons. Learn why it indicates a better outcome for the new therapy and how to interpret survival analysis results. Question What does a hazard ratio less than 1 indicate when comparing two treatments? (Assuming the standard treatment is the denominator and the new …

Read More about Data Science with Real World Data in Pharma: What Does a Hazard Ratio Less Than 1 Mean in Clinical Trial Comparisons?

Learn why hazard ratio confidence intervals crossing 1 indicate non-significant survival differences in clinical trials. Essential for Pharma Data Science certification exam prep. Question What does it mean if confidence intervals for hazard ratios cross 1? A. The survival difference is significant B. The new treatment is definitely better C. The new treatment is definitely …

Read More about Data Science with Real World Data in Pharma: What Does It Mean When Confidence Intervals for Hazard Ratios Cross 1?

Discover why metastatic cancer patients aren’t always older than in-situ cases. Explore age-related patterns in metastasis, survival outcomes, and tumor biology across breast, colorectal, and bladder cancers. Question Metastatic patients are older than patients with an in-situ disease. A. Yes, but only by a little bit B. Yes, by a large difference. C. No, that’s …

Read More about Data Science with Real World Data in Pharma: Are Metastatic Patients Older Than In-Situ Cancer Patients?